Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 7/20 | 0.48 |
| ▸ | SRC | P12931 | 2/20 | 0.47 |
| ▸ | KDR | P35968 | 4/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
| ▸ | KIF5B | P33176 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.46 |
| ▸ | FLT4 | P35916 | 2/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | INSR | P06213 | 1/20 | 0.46 |
| ▸ | FBP1 | P09467 | 1/20 | 0.46 |
| ▸ | CLK1 | P49759 | 1/20 | 0.46 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.46 |
| ▸ | TEK | Q02763 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | FLT1 | P17948 | 1/20 | 0.46 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30288418 | 1.00 | EGFR (0.48) | EGFRSRCKDRERBB2RET | |
| SCHEMBL27092833 | 0.87 | EGFR (0.40) | EGFRSRCKDRERBB2RET | |
| SCHEMBL31554502 | 0.87 | RET (0.45) | EGFRSRCKDRRETKIF5B | |
| SCHEMBL31554394 | 0.86 | ENPP1 (0.42) | EGFRSRCKDRERBB2RET | |
| SCHEMBL31554474 | 0.84 | PDGFRB (0.52) | EGFRSRCKDRPDGFRBEPHB4 | |
| SCHEMBL24009146 | 0.82 | PDPK1 (0.47) | EGFRKDRERBB2RETKIF5B | |
| SCHEMBL6786274 | 0.82 | SRC (0.48) | EGFRSRCERBB2PDGFRBPDPK1 | |
| SCHEMBL20143871 | 0.81 | PDPK1 (0.46) | EGFRSRCKDRERBB2RET | |
| SCHEMBL6335566 | 0.79 | EGFR (0.60) | EGFRSRCKDRRETKIF5B | |
| SCHEMBL6781301 | 0.79 | SRC (0.47) | EGFRSRCKDRERBB2PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6903217-B2 | Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them | AVENTIS PHARMA S.A. (FR) | 2005-06-07 | — | — | US | claimed |
| WO-2025096463-A1 | PLK4 MODULATORS | VIBLIOME THERAPEUTICS, LLC (US) | 2025-05-08 | — | — | WO | disclosed |
| US-11780849-B2 | Imino sulfanone inhibitors of ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780849-B2 | Imino sulfanone inhibitors of ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780849-B2 | Imino sulfanone inhibitors of ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| CN-115996912-A | Iminothiolanone inhibitors of ENPP1 | 沃拉斯查疗法公司 | 2023-04-21 | — | — | CN | disclosed |
| EP-4146344-A1 | IMINO SULFANONE INHIBITORS OF ENPP1 | Volastra Therapeutics, Inc. (US) | 2023-03-15 | — | — | EP | disclosed |
| US-20230002406-A1 | IMINO SULFANONE INHIBITORS OF ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | US | disclosed |
| US-20230002406-A1 | IMINO SULFANONE INHIBITORS OF ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | US | disclosed |
| CN-115362150-A | ENPP1 inhibitor, composition and application thereof | 贝达药业股份有限公司 | 2022-11-18 | — | — | CN | disclosed |
| EP-1713484-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005070891-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2005-08-04 | — | — | WO | disclosed |
| EP-0929526-B1 | QINOLINE DERIVATIVES INHIBITING THE EFFECT OF GROWTH FACTORS SUCH AS VEGF | ASTRAZENECA AB (SE) | 2005-07-27 | — | — | EP | disclosed |
| US-6809097-B1 | ANTIANGIOGENIC AND/OR VASCULAR PERMEABILITY | ZENECA LIMITED (GB) | 2004-10-26 | — | — | US | disclosed |
| US-6638945-B1 | Pharmaceutical compositions and methods of treatment of proliferative disease such as cancer using said inhibitors of specific kinase enzymes, especially MEK enzymes, as well as novel quinoline derivatives as antigrowth agents | ASTRAZENECA AB (SE) | 2003-10-28 | — | — | US | disclosed |
| EP-1178965-B1 | QUINOLINE DERIVATIVES AS INHIBITORS OF MEK ENZYMES | ASTRAZENECA AB (SE) | 2003-09-24 | — | — | EP | disclosed |
| EP-1178965-A1 | QUINOLINE DERIVATIVES AS INHIBITORS OF MEK ENZYMES | AstraZeneca AB (SE) | 2002-02-13 | — | — | EP | disclosed |
| WO-2000068199-A1 | QUINOLINE DERIVATIVES AS INHIBITORS OF MEK ENZYMES | ASTRAZENECA AB (SE) | 2000-11-16 | — | — | WO | disclosed |
| EP-0929526-A1 | QINOLINE DERIVATIVES INHIBITING THE EFFECT OF GROWTH FACTORS SUCH AS VEGF | ZENECA LIMITED (GB) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998013350-A1 | QINOLINE DERIVATIVES INHIBITING THE EFFECT OF GROWTH FACTORS SUCH AS VEGF | ZENECA LIMITED (GB) | 1998-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780849-B2 | Imino sulfanone inhibitors of ENPP1 | ENPP1, ENPP3, SMPD1 | EGFR 4147/4885SRC 1327/4885KDR 3654/4885 |
| US-20230002406-A1 | IMINO SULFANONE INHIBITORS OF ENPP1 | ENPP1, ENPP3, SMPD1 | EGFR 4147/4885SRC 1327/4885KDR 3654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.